This month’s issue of Implen’s NanoPhotometer Journal Club we are covering the work of Hannah Yejin Kim et al. who successfully validated an assay using non-invasive saliva sampling to measure linezolid in saliva samples using the NanoPhotometer® NP80 as a mobile UV-Vis spectrophotometer.
Often, in tuberculosis (TB) endemic settings therapeutic drug monitoring (TDM), which has been recommended for linezolid due to its narrow therapeutic index and drug exposure-related outcomes, is not an option. In addition to non-invasive saliva sampling, the highly affordable, mobile UV-Vis spectrophotometer will allow drug measurement at local healthcare facilities without the need to transport samples to central laboratories. There will be a significant reduction in the long turnaround time and clinicians can make prompt dose adjustment based on drug exposure. Importantly, the mobile UV-Vis spectrophotometer could be used in remote and regional settings and is a great benefit that could enable TDM of linezolid in remote settings. The mobile assay can help to establish a framework for TDM, not only for linezolid but for other drugs as well.
The saliva assay was developed using NanoPhotometer® NP80 and linezolid concentrations were quantified using second-order derivative spectroscopy. Linezolid saliva samples spiked at clinically relevant concentrations of 3.0 to 25 mg/L showed absorbance spectra with increasing magnitudes of absorbance at λmax of 250 nm correlative to linezolid concentration using second-order derivative spectra.
|